|
|
|
| June (2) 2002, Volume 29, Number 12, Pages 963-965 |
| Table of contents Previous Abstract Next Full text PDF |
 |
| Conditioning Regimens |
| Lorazepam for seizure prophylaxis during high-dose busulfan administration |
|
| K W Chan1, C A Mullen1, L L Worth1, M Choroszy1, S Koontz2, H Tran2 and J Slopis1 |
|
1Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
|
Correspondence to: Dr K W Chan, Division of Pediatrics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 87, Houston, TX 77030 USA |
|
| Abstract |
| Seizure is a recognized complication of high-dose busulfan (BU) therapy and phenytoin (DPH) is widely used as prophylaxis. A number of adverse effects have been associated with DPH and it may also interfere with BU metabolism. We used lorazepam (median dose 0.022 mg/kg) i.v. or p.o. before each dose and for 24 h after the last dose of BU as seizure prophylaxis to 29 children undergoing hematopoietic stem cell transplantation. The regimen was well tolerated and drowsiness was the only significant side-effect. Twelve patients were able to receive the entire prophylaxis by mouth. No seizure developed during and within 48 h of BU. Concomitant pharmacokinetic studies showed no alternation of the absorption and clearance of BU during lorazepam administration. Lorazepam can be used as an alternative for seizure prophylaxis during high-dose BU treatment. Bone Marrow Transplantation (2002) 29, 963-965. DOI:10.1038/sj/bmt/1703593 |
|
| Keywords |
| hematopoietic stem cell transplantation; high-dose busulfan; seizure; pediatrics; phenytoin; lorazepam |
|
|
|
|
| Received 31 January 2002; accepted 19 March 2002 |
|
| June (2) 2002, Volume 29, Number 12, Pages 963-965 |
| Table of contents Previous Abstract Next Full text PDF |
|
|
